Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma

This study has been completed.
German Hodgkin's Lymphoma Study Group
Eli Lilly and Company
Information provided by:
University of Cologne Identifier:
First received: September 2, 2005
Last updated: September 4, 2009
Last verified: September 2009
The objectives of this study are to assess the feasibility and efficacy of a combination chemotherapy (PVAG) in elderly patients with advanced stages Hodgkin's lymphoma.

Condition Intervention Phase
Hodgkin's Disease
Drug: Prednisone
Drug: Vinblastine
Drug: Doxorubicin (Adriamycin)
Drug: Gemcitabine
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: PVAG - Phase I/II Dose Finding Trial in Elderly Patients (> 60 Years) With Advanced Stages Hodgkin's Lymphoma

Resource links provided by NLM:

Further study details as provided by University of Cologne:

Primary Outcome Measures:
  • Phase I: Dose-limiting toxicities and dose reductions
  • Phase II: Treatment administration and complete response rate

Secondary Outcome Measures:
  • Toxicities
  • Supportive care (RBCT need, antibiotic need)
  • Early progression rate
  • Overall survival

Enrollment: 60
Study Start Date: March 2004
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Detailed Description:
Gemcitabine shows promising activity in patients with relapsed lymphoma either administered as single agent or in combination with other cytotoxic agents. No trial to date evaluated its role in patients with primary Hodgkin's lymphoma. We therefore developed a three-weekly regimen based on the standard ABVD regimen.

Ages Eligible for Study:   60 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hodgkin's lymphoma (histologically proven)
  • Clinical stage IIB (with risk factors bulky mediastinal mass and/or extranodal involvement), III, or IV
  • No prior antitumor therapy
  • Age 60 to 75 years
  • WHO performance status 0-2
  • Normal pulmonary function
  • Written informed consent

Exclusion Criteria:

  • The following histologies are excluded: lymphocyte predominant HD
  • Leukocytes < 2,500/microL
  • Platelets < 100,000/microL
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00147875

University of Cologne
Cologne, NRW, Germany, 50924
Sponsors and Collaborators
University of Cologne
German Hodgkin's Lymphoma Study Group
Eli Lilly and Company
Principal Investigator: Andreas Engert University of Cologne
  More Information

No publications provided by University of Cologne

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00147875     History of Changes
Other Study ID Numbers: PVAG elderly 
Study First Received: September 2, 2005
Last Updated: September 4, 2009
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University of Cologne:
Advanced stages Hodgkin's lymphoma

Additional relevant MeSH terms:
Hodgkin Disease
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Liposomal doxorubicin
Anti-Infective Agents
Anti-Inflammatory Agents
Antibiotics, Antineoplastic
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators processed this record on February 11, 2016